ArticleFrontiers in oncology2025
Surgical management of biliary fistula following associating liver partition and portal vein ligation for staged hepatectomy in pediatric hepatoblastoma: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report the clinical data of a pediatric patient with massive hepatoblastoma who underwent associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) following chemotherapy. Case presentation: A 1-year-and-8-month-old male infant was diagnosed prenatally with an intrahepatic mass, which was later confirmed as hepatoblastoma via ultrasound-guided biopsy postnatally. The parents declined surgical intervention, leading to voluntary discharge. The child received oral lenvatinib therapy externally, but the tumor continued to enlarge (13.1cm × 7.9cm × 9.9cm), prompting hospital admission. Four cycles of C5VD chemotherapy (cisplatin + vincristine + 5-fluorouracil) were administered, resulting in limited tumor reduction (11.3cm × 5.6cm × 10.8cm). Minimal shrinkage was observed after the fourth cycle compared to the second, with significant intratumoral calcification, suggesting suboptimal further chemotherapeutic efficacy. Surgical intervention was thus decided. Preoperative assessment indicated that direct tumor resection would leave only 24% of the future liver remnant, posing a high risk of liver failure. ALPPS was consequently selected. During the first stage (February 25, 2025), liver partition and right portal vein ligation were performed. Ten days postoperatively, FLR increased to 35%, enabling the second-stage tumor resection (March 9, 2025). Postoperative biliary fistula developed at the liver transection plane and failed conservative management, necessitating a third procedure (hepaticojejunostomy via Roux-en-Y anastomosis) for successful biliary-enteric drainage reconstruction. Adjuvant chemotherapy was continued postoperatively, with no recurrence observed during follow-up. Conclusion: ALPPS is a safe and effective surgical approach for pediatric patients with massive hepatoblastoma requiring extensive resection and presenting with insufficient FLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.